

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: [Kaneh Bosm Biotechnology Inc.](#) (the "Issuer").

Trading Symbol: [KBB](#)

Number of Outstanding Listed Securities: [141,219,108 common shares were issued and outstanding as of June 30, 2018.](#)

Date: [July 6, 2018 \(for the month of June, 2018\)](#)

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.
[The Issuer continues to evaluate potential marijuana projects and cannabis related companies for potential acquisition and growth.](#)
2. Provide a general overview and discussion of the activities of management.

During the month of **June 2018**, management was very active with its corporate and business development endeavours, which included the following transactions or material events:

- The Issuer closed two previously announced transactions with Marathon Global Inc. ("**Marathon**") and acquired 50% of the issued and outstanding share capital of Marathon as announced in the Issuer's news release dated June 6, 2018;
- The Issuer entered into a definitive agreement with 2635835 Ontario Inc. dba Canafrica Holdings ("**Canafrica**"), a private Ontario corporation, as announced on June 7, 2018 to acquire all of the issued capital of Canafrica by way of a three cornered amalgamation (the "**Acquisition**"). Canafrica holds a license to cultivate, manufacture, supply, hold, import, export and transport cannabis and derivative products in the Kingdom of Lesotho, Africa. The Issuer announced that it closed the Acquisition on June 19, 2018;
- The Issuer announced on June 13, 2018, that Mr. Peter Nguyen has been appointed as the Issuer's Chief Financial Officer, following the resignation of Mr. Anthony Jackson;
- The Issuer announced that it had closed a non-brokered private placement on June 19, 2018. The Issuer issued 10,000,000 units ("**Units**") at a price of \$0.50 per Unit for gross proceeds of \$5,000,000. Each Unit is comprised of one common share (a "**Share**") and one common share purchase warrant (a "**Warrant**"). Each Warrant shall entitle the holder thereof to acquire one additional Share at a price of \$1.00 per Warrant for a period of 12 months from issuance;
- The Issuer announced on June 21, 2018, that it had entered into a binding letter of intent (the "**LOI**") with 2629429 Ontario Inc., ("**2629429**") a private Ontario corporation; to acquire 100% of the issued and outstanding share capital of 2629429 by way of a three cornered amalgamation (the "**2629429 Acquisition**"). 2629429 through its wholly-owned Colombian subsidiary, Cannabis Medical Group SAS, holds licences to cultivate, produce, hold, sell and export cannabis and its by-products in Colombia. The Issuer announced that it had closed the 2629429 Acquisition on June 28, 2018;
- The Issuer announced on June 22, 2018, that it had granted 7,591,911 incentive stock options to its directors, officers, employees and consultants with an exercise price of \$0.51 per Share for a period of up to 5 years;
- The Issuer announced on June 26, 2018, that it has entered into a definitive agreement with Marathon to acquire the remaining 50% of its issued and outstanding share capital. The Issuer announced that it had closed the transaction on June 28, 2018;

- [The Issuer announced on June 28, 2018, the appointment of Mr. Brendan Purdy to its board of directors and Mr. Eugene Beukman as its Chief Executive Officer, the appointments follow the resignation of Mr. Rudy de Jonge;](#)
 - [The Issuer announced on June 29, 2018, that it has entered into a definitive agreement with EU Cannabis Corp. \(“EU Cannabis”\) to acquire 100% of EU Cannabis’ issued and outstanding share capital. EU Cannabis has an option to acquire a 90% working interest in industrial hemp licenses \(“Licenses”\) held by Cannatec Greece A.E. \(“Cannatec”\). Cannatec currently holds three Licenses covering a total of 16 acres situated within the Greek prefecture of Imathia.](#)
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
- [There were no new products or services developed or offered during the month of June 2018.](#)
4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.
- [There were no products or services discontinued during the month of June 2018.](#)
5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

[During the month of June 2018, the Issuer entered into an acquisition agreement \(the “**Acquisition Agreement**”\) with the shareholders of Canafrica \(the “**Vendors**”\) which provided for the exchange on a basis of 1-to-275,700 of all of the shares of Canafrica held by the Vendors into common shares in the capital of the Issuer. Pursuant to the terms of the Acquisition Agreement, and the terms of an amalgamation agreement \(the “**Amalgamation Agreement**”\), also dated June 1, 2018, the Issuer issued 29,500,000 Shares to the Vendors, paid \\$1,300,000 and Canafrica amalgamated with the Issuer’s wholly-owned subsidiary. Upon amalgamation, Canafrica became a wholly-owned subsidiary of the Issuer](#)

[The Issuer entered into a LOI with the shareholders of 2629429 \(the “**2629429 Vendors**”\) which provided for the exchange on a basis of 1-to-100,000 of all of the shares of 2629429 held by the 2629429 Vendors into common shares in the capital of the Issuer. Pursuant to the terms of the LOI, and the terms of the amalgamation agreement \(the “**2629429 Amalgamation Agreement**”\), dated June 25, 2018, the Issuer issued 30,000,000 Shares and paid \\$2,000,000 USD to the 2629429 Vendors and 2629429 amalgamated with the Issuer’s wholly-](#)

owned subsidiary, Canna Colombia Holdings Inc., created solely to close this transaction. Upon amalgamation with Canna Colombia, 2629429 became a wholly-owned subsidiary of the Issuer.

The Issuer entered into a second share exchange agreement (the “**Share Exchange Agreement**”) with Marathon to acquire the remaining 50% of its issued and outstanding share capital. Marathon has an exclusive agreement with Cosmos Holdings, an EU Pharmaceutical distributor to procure and distribute medical cannabis products and all cannabis derivatives for its 110 client distribution network in 16 approved countries representing approximately 35,000 pharmacies. Pursuant to the terms of the Agreement, the Issuer issued 15,000,000 Shares to certain shareholders of Marathon in exchange for 8,500,000 Shares of Marathon.

The Issuer entered into a definitive agreement (the “**Agreement**”) with EU Cannabis to acquire 100% of EU Cannabis’ issued and outstanding share capital. EU Cannabis has an option to acquire a 90% working interest in “Licenses” held by Cannatec. Cannatec currently holds three Licenses covering a total of 16 acres situated within the Greek prefecture of Imathia. Pursuant to the terms of the Agreement, the Issuer will pay \$250,000 USD to EU Cannabis and it will issue 18,000,000 Shares to the shareholders of EU Cannabis.

Each of the agreements noted above are at arm’s length to the Issuer.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

There were no contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced, expired or was terminated during the month of **June 2018**.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

During the month of **May 2018**, the Issuer entered into a share exchange agreement (the “**Share Exchange Agreement**”) with Marathon Global Inc. (“**Marathon**”) to acquire 44.12% of its issued and outstanding share capital. Marathon has an exclusive agreement with Cosmos Holdings Inc., an EU Pharmaceutical distributor to procure and distribute medical cannabis products and all cannabis derivatives for its 110 client distribution network in 16 approved countries representing approximately 35,000 pharmacies. Pursuant to the terms of the Agreement, the Issuer issued 15,000,000 Shares to certain shareholders of Marathon in exchange for 7,500,000 Shares of Marathon.

The Issuer also entered into a share purchase agreement (the “Share Purchase Agreement”) with Marathon to acquire an additional 1,000,000 Shares of Marathon at a price of \$1.00 per Share. Following closing of both agreements, the Issuer acquired 50% of the issued and outstanding share capital of Marathon.

8. Describe the acquisition of new customers or loss of customers.

There were no acquisitions of new customers or loss of customers during the month of **June 2018**.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

There were no new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks during the month of **June 2018**.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

There were no employee hirings, terminations or lay-offs during the month of **June 2018**.

11. Report on any labour disputes and resolutions of those disputes if applicable.

There were no labour disputes during the month of **June 2018**.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

There were no legal proceedings to which the Issuer became party to during the month of **June 2018**.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

There was no indebtedness incurred or repaid by the Issuer during the month of **June 2018**.

14. Provide details of any securities issued and options or warrants granted.

During the month of **June 2018**, the following securities were issued:

Security	Number Issued	Details of Issuance	Use of Proceeds
Common Shares	16,200,000	Acquisition of Marathon	N/A
Common Shares	11,400,000	Acquisition of Canafrica	N/A
Common Shares	50,000	Exercise of stock options	Working Capital
Common shares	20,460,000	Acquisition of Canafrica	N/A
Units ⁽¹⁾	10,000,000	Private Placement of Units issued at a \$0.50 per Unit	Working capital
Stock Options ⁽²⁾	7,591,911	Stock Option Grant to Directors, Officers, Employees and Consultants	Proceeds received from the exercise of Stock Options will be used for working capital.
Common Shares	30,000	Exercise of stock options	Working capital
Common Shares	32,400,000	Acquisition of 2629429	N/A
Common Shares	16,200,000	Acquisition of remaining 50% share capital of Marathon	N/A

(1) Each Unit is comprised of one Share and One Warrant. Each Warrant shall entitle the holder thereof to acquire one additional Share at a price of \$1.00 per Warrant for a period of 12 months from issuance.

(2) Each Stock Option is exercisable by the holder to acquire one Share a price of \$0.51 for a period of 5 years from grant.

15. Provide details of any loans to or by Related Persons.

There were no loans to or by Related Persons of the Issuer during the month of June 2018.

16. Provide details of any changes in directors, officers or committee members.

On June 13, 2018, the Issuer announced that it has appointed Mr. Peter Nguyen as its Chief Financial Officer following the resignation of Mr. Anthony Jackson.

On June 28, 2018, Mr. Rudy de Jonge resigned as a director and as the Issuer's Chief Executive Officer. Mr. Brendan Purdy was appointed to replace Mr. de Jonge on the board of directors and Mr. Eugene Beukman was appointed as the Issuer's Chief Executive Officer.

Following Mr. de Jonge's resignation, the Issuer's audit Committee is comprised of Messrs. Purdy, Beukman and Martinz.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

Limited Operating History

Other than the sale of one Kiosk System, the Company has yet to generate any revenue.

The Market Price of the Shares May be Subject to Wide Price Fluctuations

The market price of the Shares may be subject to wide fluctuations in response to many factors, including variations in the operating results of the Company, divergence in financial results from analysts' expectations, changes in earnings estimates by stock market analysts, changes in the business prospects for the Company, general economic conditions, legislative changes, and other events and factors outside of the Company's control. In addition, stock markets have from time to time experienced extreme price and volume fluctuations, which, as well as general economic and political conditions, could adversely affect the market price of the Shares.

The Market Price of the Shares May be Subject to Wide Price Fluctuations

The Company has incurred net losses to date. Its deficit as of November 30, 2017 is \$4,349,746. During the year ended February 29, 2016, the Company has generated revenues of \$51,558 from the sale of one Kiosk System. There is no certainty that the Company will find a viable enterprise or produce revenue, operate profitably or provide a return on investment in the future.

Additional Financing

The Company will be required to continue to sell its securities to raise cash until it has a revenue generating asset. At this time the Company is searching for a viable asset.

Risks Associated with the Cannabis sector

Other than the sale of one Kiosk System and despite the Company's best efforts, it has been unsuccessful to date in acceptance of its Kiosk System for the dispensing of cannabis products. There is no assurance that the Kiosk System will be accepted for the dispensing of recreational and medical cannabis products after July 1, 2018. The provinces of Canada ("Provinces") are responsible for the regulations regarding the dispensing and sale of recreational marijuana and these regulations are not uniform among the Provinces or settled. Discussions of the regulations have included dispensing through existing government facilities such as liquor stores and through licensed pharmacies. There is no assurance that the Kiosk System will be accepted for dispensing any cannabis products in the Provinces.

Competition

There is potential that other companies with established operating businesses and the funds to operate facilities accepted by the Provinces for dispensing cannabis products will establish themselves as the dispensary of choice.

[the balance of this page is intentionally blank]

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated July 6, 2018.

Eugene Beukman
Name of Director or Senior
Officer

"Eugene Beukman"
Signature
Chief Executive Officer
Official Capacity

Issuer Details		For Month	Date of Report
Name of Issuer	End	YY/MM/D	
Kaneh Bosm Biotechnology Inc.	June 2018	18/07/06	
Issuer Address			
810 – 789 West Pender Street			
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.	
Vancouver, BC V6C 1H	604-687-3141	604-687-2308	
Contact Name	Contact Position	Contact Telephone No.	
Eugene Beukman	CEO, Director	604-782-4191	
Contact Email Address	Web Site Address		
Ebeukman@pendergroup.ca	N/A		